【百时美施贵宝的皮下注射抗癌药物Opdivo获FDA批准】美国食品药品管理局(FDA)上周五宣布,已批准百时美施贵宝公司的皮下注射Opdivo Qvantig上市。该皮下注射剂已获批用于治疗所有之前获批的成人实体瘤适应症,可单独使用、作为维持治疗或与化疗联合使用。此次批准基于一项后期研究的数据,该研究显示,对于接受过全身治疗的晚期肾癌患者,皮下注射药物的效果并不逊于静脉注射药物。随着抗癌药物Revlimid和血液稀释剂Eliquis等专利将在本世纪末到期,百时美施贵宝正依靠Opdivo Qvantig等新疗法来推动增长。

金融界
30 Dec 2024
美国食品药品管理局(FDA)上周五宣布,已批准百时美施贵宝公司的皮下注射Opdivo Qvantig上市。该皮下注射剂已获批用于治疗所有之前获批的成人实体瘤适应症,可单独使用、作为维持治疗或与化疗联合使用。此次批准基于一项后期研究的数据,该研究显示,对于接受过全身治疗的晚期肾癌患者,皮下注射药物的效果并不逊于静脉注射药物。随着抗癌药物Revlimid和血液稀释剂Eliquis等专利将在本世纪末到期,百时美施贵宝正依靠Opdivo Qvantig等新疗法来推动增长。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10